A detailed history of Portolan Capital Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Portolan Capital Management, LLC holds 60,976 shares of ALT stock, worth $473,173. This represents 0.03% of its overall portfolio holdings.

Number of Shares
60,976
Previous 640,242 90.48%
Holding current value
$473,173
Previous $4.26 Million 91.21%
% of portfolio
0.03%
Previous 0.38%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.5 - $8.1 $3.19 Million - $4.69 Million
-579,266 Reduced 90.48%
60,976 $374,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $1.46 Million - $2.53 Million
-247,013 Reduced 27.84%
640,242 $4.26 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $7.29 Million - $12.3 Million
887,255 New
887,255 $9.03 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $380M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Portolan Capital Management, LLC Portfolio

Follow Portolan Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Portolan Capital Management, LLC with notifications on news.